Search bioRxiv⌕ Search

Biology subjects

Regensburger, M.

Publications and source records attributed to Regensburger, M..

4 recordsLinked to original sources

Human blood vessel organoids recapitulate key mechanisms of transition from vasculopathy to fibrosis in systemic sclerosis

Systemic sclerosis (SSc) is an autoimmune disease that transitions from vasculopathy as an initiating pathogenic event to tissue fibrosis. The mechanisms of these transitions remain, however, poorly understood, mainly because complex multicellular human models of SSc vasculopathy are lacking. Here we characterized blood vessel organoids (BVOs) as a novel model system of vasculopathy in SSc. We demonstrate that exposure of SSc-BVOs to SSc serum triggers changes on epigenetic, mRNA and protein levels and recapitulates key pathogenic features of SSc vasculopathy, with shifts from angiogenic endothelial cell subsets to those undergoing endothelial-to-mesenchymal transition, loss of endothelial cells-pericytes interactions and profound angiogenic defects. The genetic predisposition of SSc donors and serum IgGs are required for the deleterious effects of SSc serum. We further validate SSc-BVOs as a human model system to evaluate candidate therapies targeting SSc microvasculopathy and use this system to provide evidence that {gamma}-secretase inhibition is a potential therapeutic approach.

biophysics↗

Deciphering Brain Organoids Heterogeneity by Identifying Key Quality Determinants

Brain organoids derived from human pluripotent stem cells (hPSCs) hold immense potential for modeling neurodevelopmental processes and disorders. However, their experimental variability and undefined organoid selection criteria for analysis hinder reproducibility. As part of the Bavarian ForInter consortium, we generated 72 brain organoids from distinct hPSC lines. We conducted a comprehensive analysis of their morphological and cellular characteristics at an early stage of their development. In our assessment, the Feret diameter emerged as a reliable, single parameter that characterizes brain organoid quality. Transcriptomic analysis further confirmed the reliability of this marker and identified a negative impact of mesenchymal cells on the abundance of organoid formation. High-quality organoids consistently displayed a lower mesenchymal cell presence. These findings offer a framework for enhancing brain organoid standardization and reproducibility, underscoring the need for morphological quality controls and the consideration of mesenchymal cell influence on organoid-based modeling. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=186 HEIGHT=200 SRC="FIGDIR/small/632763v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@11c214org.highwire.dtl.DTLVardef@1dcb643org.highwire.dtl.DTLVardef@1420141org.highwire.dtl.DTLVardef@6074e6_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

RNA splicing modulator induces peripheral neuropathy with increased neurofilament light chain levels via p53 signaling

RNA splicing modulators are a new class of small molecules with the potential to modify the expression levels of proteins. A recent clinical trial investigating the splicing modulator branaplam for Huntingtons disease to lower huntingtin levels was terminated due to the development of peripheral neuropathy. Here, we describe how branaplam leads to this adverse effect. On a cellular level, branaplam disrupts neurite integrity reflected by elevated neurofilament light chain levels in human induced pluripotent stem cell (iPSC)-derived motor neurons (iPSC-MN). Branaplam does not target neuropathy-associated genes. However, transcription factor binding site enrichment analysis indicates p53 activation. P53 activation upon branaplam treatment in iPSC-MN is linked to increased nucleolar stress, thereby enhanced expression of the neurotoxic p53-target gene BBC3. These findings illustrate that RNA splicing modulators may have clinically relevant off-target effects, implying the necessity of comprehensive pre-screening in human models prior to executing clinical trials. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=188 SRC="FIGDIR/small/551640v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@9b2cbdorg.highwire.dtl.DTLVardef@1964746org.highwire.dtl.DTLVardef@121612corg.highwire.dtl.DTLVardef@72c6a6_HPS_FORMAT_FIGEXP M_FIG C_FIG One Sentence SummaryPredicting side effects of RNA splicing modulator branaplam leading to neurotoxicity via nucleolar stress, p53 activation, and axonal degeneration.

pharmacology and toxicology↗

Need for high-resolution Genetic Analysis in iPSC: Results and Lessons from the ForIPS Consortium

Genetic integrity of induced pluripotent stem cells (iPSCs) is essential for their validity as disease models and for potential therapeutic use. We describe the comprehensive analysis in the ForIPS consortium: an iPSC collection from donors with neurological diseases and healthy controls. Characterization included pluripotency confirmation, fingerprinting, conventional and molecular karyotyping in all lines. In the majority, somatic copy number variants (CNVs) were identified. A subset with available matched donor DNA was selected for comparative exome sequencing. We identified single nucleotide variants (SNVs) at different allelic frequencies in each clone with high variability in mutational load. Low frequencies of variants in parental fibroblasts highlight the importance of germline samples. Somatic variant number was independent from reprogramming, cell type and passage. Comparison with disease genes and prediction scores suggest biological relevance for some variants. We show that high-throughput sequencing has value beyond SNV detection and the requirement to individually evaluate each clone.

genomics↗